Biotest competitive analysis

Explore patent oppositions filed by Biotest against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
Human Blood-Derived Products Having Decreased Fibrinolytic Activity And Uses Thereof In Hemostatic DisordersPLAS FREEDec 5, 2024
Stable Liquid FibrinogenLABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESJun 5, 2024
Methods For Isolating Blood Products From An Inter-Alpha Inhibitor Protein-Depleted Blood Product MaterialPROTHERA BIOLOGICSJan 17, 2020
Method For Inactivation/Removal Of Coagulation Factors By PrecipitationOCTAPHARMADec 21, 2018
Improved Process For Production Of Fibrinogen And Fibrinogen Produced TherebyOCTAPHARMAApr 12, 2018
Method For Preparing A Depleted Plasma Material Consisting Of One Or More Thrombogenic FactorsLABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESNov 8, 2017
Immunoglobulin PurificationF HOFFMANN LA ROCHEMar 24, 2015

Explore Biotest's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
Apr 29, 2026Process For Preparing An Immunoglobulin Composition1
Jan 17, 2024Antibody Preparations1

Latest PTAB cases involving Biotest

Discover the latest PTAB cases involving Biotest, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Biotest with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BIOTEST72 - -
LABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES - 20 - -
OCTAPHARMA1110 - -
STRAWMAN468 - - -